Months After Approval, Breakthrough Cancer Drug Given to Just Five Patients

Bloomberg
Bloomberg
Dec 14, 2017 · 5 min read
Photographer: David Paul Morris/Bloomberg

By Michelle Fay Cortez, Caroline Chen, and Natasha Rausch

Two months after Gilead Sciences Inc.’s breakthrough treatment was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, while others linger on waiting lists.

To keep reading this story, get the free app or log in.
Read the rest of this story with a free account.

Medium is an open platform where 170 million readers come to find insightful and dynamic thinking. Here, expert and undiscovered voices alike dive into the heart of any topic and bring new ideas to the surface. Learn more

Follow the writers, publications, and topics that matter to you, and you’ll see them on your homepage and in your inbox. Explore

If you have a story to tell, knowledge to share, or a perspective to offer — welcome home. It’s easy and free to post your thinking on any topic. Write on Medium

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store